ChinaDaily Briefs

Daily Brief China: Inner Mongolia Yitai Coal Company Ltd, Tencent, Alibaba Group, KE Holdings Inc, BeiGene, AviChina Industry & Technology H, Sino-Ocean Group and more

In today’s briefing:

  • Yitai Coal (3948 HK): H-Share Offer (Likely) Imminent
  • Yitai Coal (3948 HK): H Share Buyback Offer at HK$17.50 Per H Share
  • Tencent (700 HK) Earnings Preview: To See Recovery in 1Q23
  • Yitai Coal (3948 HK): H-Share Buyback Firmed At HK$17.50
  • Alibaba (9988 HK) Earnings Preview: Better Growth and Better Margin for 4Q23
  • [KE Holdings Inc. (BEKE US) Target Price Change]: Government Clears the Commission Uncertainties
  • [BeiGene, LTD. (BGNE US) Target Price Change]: Valuation Adjustment Can Drive the Stock Upside
  • AviChina Industry (2357 HK): Benefiting from the Geopolitical Turmoil
  • Morning Views Asia: JSW Steel Ltd, Powerlong Commercial Management Holdings, Sino-Ocean Service

Yitai Coal (3948 HK): H-Share Offer (Likely) Imminent

By David Blennerhassett

  • Back on the 29 March, Inner Mongolia Yitai Coal Company Ltd (3948 HK) announced a possible H-share buyback at HK$17/share, a 50.4% premium to the undisturbed price.
  • Yitai Coal is PRC-incorporated, therefore it is not afforded compulsory acquisition rights. To buy back ALL H-shares, either a Merger by Acquisition or a Voluntary Conditional Offer is required.
  • The Offer/buyback, should it proceed, is subject to various PRC regulatory approvals, including SAFE; together with approval from Yitai Coal’s A/H shareholders. To date, the SAFE Registration has been completed.

Yitai Coal (3948 HK): H Share Buyback Offer at HK$17.50 Per H Share

By Arun George

  • Inner Mongolia Yitai Coal Company Ltd (3948 HK)‘s H Share buyback offer is at HK$17.50, a 54.9% premium to the undisturbed price and a 9.0% premium to the last close. 
  • The key conditions are approval by at least 75% of independent H Shareholders (<10% of all independent H Shareholders rejection). There is a 90% minimum acceptance condition.  
  • The three independent H shareholders holding a blocking stake will be supportive of the attractive offer (9-year H Share price high). The price is final. Timing is the key risk.

Tencent (700 HK) Earnings Preview: To See Recovery in 1Q23

By Ming Lu

  • We believe total revenue will grow by 6% in 1Q23, compared to four stagnant quarters in 2022.
  • We also believe operating margin will improve by 2 percentage points YoY in 1Q23 due to the layoff in 1Q22.
  • We believe the stock has an upside of 48%, but we reduce our price target from HK$563 to HK$505.

Yitai Coal (3948 HK): H-Share Buyback Firmed At HK$17.50

By David Blennerhassett

  • Timing is everything. Yesterday afternoon I flagged Inner Mongolia Yitai Coal Company Ltd (3948 HK)‘s possible H-share buyback at HK$17/share.
  • Roughly five hours later a firm HK$17.50/share Offer was announced. The Offer Price is final.
  • Other terms and approvals were largely as expected. Payment under the Offer may occur mid-August.

Alibaba (9988 HK) Earnings Preview: Better Growth and Better Margin for 4Q23

By Ming Lu

  • We believe revenue will grow by 5.6% YoY in 4Q23 and by 9% in FY2023 versus 2.7% in FY2022.
  • We also believe operating margin will improve slightly to 8.9% in 4Q23 versus 8.2% in 4Q22.
  • We believe the stock has an upside of 63% for March 2024.

[KE Holdings Inc. (BEKE US) Target Price Change]: Government Clears the Commission Uncertainties

By Shawn Yang

  • China government guided no commission capping on real estate brokerage business, but the ladder-pricing system may lead to moderate commission rate reduction for Beike.
  • We estimate that 0.1% of Lianjia commission rate cut can imply to 1.2% of revenue reduction for Beike in 2023. 
  • Therefore, we lowered revenue by (2.8%) and net income by (5.3%) to factor in the potential changes.  We maintain BUY rating but cut the TP by US$2 to US$21.  

[BeiGene, LTD. (BGNE US) Target Price Change]: Valuation Adjustment Can Drive the Stock Upside

By Shawn Yang

  • BeiGene (BGNE) reported C1Q23 top line 7% and gross margin 1.5ppt above our estimates, leading to non-GAA operating loss 23% narrower than our estimate. 
  • We raise BRUKINSA’s peak year sales from US$5bn to US$5.8bn while cutting Tislelizumab’s peak sales from US$1.5bn to US$1.2bn. 
  • With transition to a biopharma complete, BGNE should enjoy a higher multiple; We raised TP from US$219 to US$254 and maintain BUY.

AviChina Industry (2357 HK): Benefiting from the Geopolitical Turmoil

By Osbert Tang, CFA

  • AviChina Industry & Technology (2357 HK) remains cheap with 3-year earnings CAGR of 17.4% but only 11x PER. It also trades on 55% discount to value of its A-share subsidiaries.
  • Aggregate earnings for its four A-share listed subsidiaries grew a solid 26.8% in 1Q23, even faster than AviChina Industry’s FY23F earnings growth of 21.5%. 
  • China is expected to increase military spending to narrow the gap against the US going forward. AviChina stays best exposed to such growth in defense demand.

Morning Views Asia: JSW Steel Ltd, Powerlong Commercial Management Holdings, Sino-Ocean Service

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars